Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rowe

Showing results (471-480 of 632) with videos related to

Pageof 64
Sort By:
Diagnostics (Basel, Switzerland)|April 30, 2021
Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate CancerWajahat Khatri, Hyun Woo Chung, Rudolf A Werner, et al.
Annals of Nuclear Medicine|March 17, 2019
<sup>18</sup>F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studiesSara Sheikhbahaei, Krystyna M Jones, Rudolf A Werner, et al.
The Journal of Biological Chemistry|May 12, 2005
Unraveling the mechanism of a potent transcriptional activatorZhen Lu, Steven P Rowe, Brian B Brennan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 10, 2016
Semiquantitative Parameters in PSMA-Targeted PET Imaging with <sup>18</sup>F-DCFPyL: Variability in Normal-Organ UptakeXin Li, Steven P Rowe, Jeffrey P Leal, et al.
Nuklearmedizin. Nuclear Medicine|January 14, 2022
[18F]DCFPyL PET/CT for Imaging of Prostate CancerSteven P Rowe, Andreas Buck, Ralph A Bundschuh, et al.
Radiology|March 31, 2021
Prostate-specific Membrane Antigen PET in Prostate CancerCourtney Lawhn-Heath, Ali Salavati, Spencer C Behr, et al.
Toxins|April 23, 2020
Defensive Venoms: Is Pain Sufficient for Predator Deterrence?Crystal N Niermann, Travis G Tate, Amber L Suto, et al.
Radiologic Clinics of North America|November 16, 2023
Prostate-Specific Membrane Antigen-Ligand Therapy: What the Radiologist Needs to KnowSteven P Rowe, Mohammad S Sadaghiani, Andrei Gafita, et al.
Clinical Nuclear Medicine|May 11, 2023
Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System TumorsAlexander Weich, Sebastian E Serfling, Wiebke Schlötelburg, et al.
Nuklearmedizin. Nuclear Medicine|August 17, 2022
Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an [18F]FDG PET/CT in Patients with Giant Cell ArteritisKonstanze V Guggenberger, Marius L Vogt, Steven P Rowe, et al.
Pageof 64

Showing results (471-480 of 632) with videos related to

Sort By:
Pageof 64
Diagnostics (Basel, Switzerland)|April 30, 2021
Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate CancerWajahat Khatri, Hyun Woo Chung, Rudolf A Werner, et al.
Annals of Nuclear Medicine|March 17, 2019
<sup>18</sup>F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studiesSara Sheikhbahaei, Krystyna M Jones, Rudolf A Werner, et al.
The Journal of Biological Chemistry|May 12, 2005
Unraveling the mechanism of a potent transcriptional activatorZhen Lu, Steven P Rowe, Brian B Brennan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 10, 2016
Semiquantitative Parameters in PSMA-Targeted PET Imaging with <sup>18</sup>F-DCFPyL: Variability in Normal-Organ UptakeXin Li, Steven P Rowe, Jeffrey P Leal, et al.
Nuklearmedizin. Nuclear Medicine|January 14, 2022
[18F]DCFPyL PET/CT for Imaging of Prostate CancerSteven P Rowe, Andreas Buck, Ralph A Bundschuh, et al.
Radiology|March 31, 2021
Prostate-specific Membrane Antigen PET in Prostate CancerCourtney Lawhn-Heath, Ali Salavati, Spencer C Behr, et al.
Toxins|April 23, 2020
Defensive Venoms: Is Pain Sufficient for Predator Deterrence?Crystal N Niermann, Travis G Tate, Amber L Suto, et al.
Radiologic Clinics of North America|November 16, 2023
Prostate-Specific Membrane Antigen-Ligand Therapy: What the Radiologist Needs to KnowSteven P Rowe, Mohammad S Sadaghiani, Andrei Gafita, et al.
Clinical Nuclear Medicine|May 11, 2023
Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System TumorsAlexander Weich, Sebastian E Serfling, Wiebke Schlötelburg, et al.
Nuklearmedizin. Nuclear Medicine|August 17, 2022
Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an [18F]FDG PET/CT in Patients with Giant Cell ArteritisKonstanze V Guggenberger, Marius L Vogt, Steven P Rowe, et al.
Pageof 64